The LEO Pharma Open Innovation is open for any official institution or registered company with molecules to test, such as (but not limited to):
- SMEs/Biotech companies – could be early molecules with relevant in vitro and/or in vivo results and science that can overlap with that of LEO Pharma for in-licensing or collaborative drug discovery.
- University groups – University department with molecules holding unique properties, both for exploring targets as well as novel treatment opportunities.
- Pharmaceutical companies - with shelved or unused molecules.
- Anyone else -We engage with others who are involved in healthcare and research, such as students, patients and investors. If you are interested in participating in the open innovation platform and open community, please get in touch